Hemorrhagic Stroke Treatment Market By Treatment Type (Drug Therapy, Surgical Intervention, Endovascular Procedures, Monitoring & Supportive Devices); By Cause/Condition (Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Other Rare Hemorrhages); By End User (Tertiary Hospitals, General Hospitals, Ambulatory Surgical Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Hemorrhagic Stroke Treatment Market Scales Through ICU Severity, Aneurysm Repair, and Selective Device Evidence

The Global Hemorrhagic Stroke Treatment Market was valued at USD 4.12 billion in 2025 and is projected to reach USD 6.27 billion by 2032, growing at a CAGR of 6.13%, according to Strategic Market Research.

 

Hemorrhagic stroke treatment is concentrated in hospitals and specialist neurovascular centres. Care spans intracerebral haemorrhage, aneurysmal subarachnoid haemorrhage, anticoagulant reversal, neurocritical care, aneurysm clipping or coiling, ventricular drainage, and selected minimally invasive evacuation procedures.

 

Treatment access depends on rapid transfer, imaging, clinical eligibility, and specialist capability. Commercial demand is therefore strongest for reversal agents, neurovascular devices, surgical systems, ICU protocols, and therapies used in aneurysmal subarachnoid haemorrhage.

 

Treatment Demand and Patient Base

Intracerebral hemorrhage provides the largest acute-care base. In 2021, there were 3.444 million new ICH cases, 3.308 million deaths, and 79.457 million DALYs globally. ICH accounts for a smaller share of total stroke incidence than ischemic stroke, but it carries a disproportionate share of stroke mortality and disability. Hospitals, device suppliers, reversal-product manufacturers, and neurocritical care providers therefore compete in a high-severity emergency setting rather than a broad chronic-treatment market.

Recent incidence and outcome data place greater emphasis on functional recovery than clot reduction alone. A systematic review of 70 studies across 26 countries reported an ICH incidence of 29.2 per 100,000 person-years, one-month mortality of 35.5%, and good functional recovery in only 31.2% of patients at three to 12 months. Treatments that improve survival, discharge outcomes, independence, ICU use, or long-term disability are likely to gain broader clinical adoption than those showing benefit only on imaging.

Subarachnoid hemorrhage is smaller but more concentrated in specialist centers. A 2025 GBD 2021 analysis estimated about 700,000 new SAH cases, nearly 8 million prevalent SAH cases, 350,000 deaths, and more than 10 million SAH-related DALYs globally in 2021. Aneurysmal SAH patients often require aneurysm repair, neurocritical monitoring, nimodipine, vasospasm surveillance, external ventricular drainage, and prolonged inpatient care. Procedure intensity gives SAH a larger commercial role than its incidence share suggests.

The U.S. market is better measured through hospital-treated cases than total stroke prevalence. A 2022 National Inpatient Sample analysis identified 78,685 weighted ICH hospitalizations, with 20.2% inpatient mortality, a 9.9-day mean length of stay, and mean hospital charges above USD 160,000. Emergency drugs, imaging, ICU care, surgical devices, reversal products, and discharge-management services all compete for budget inside this inpatient episode.

China carries one of the largest single-country ICH burdens. The China Stroke Prevention and Control Report 2024 reported about 4.09 million new stroke cases in 2021, including 1.17 million intracerebral hemorrhages. Advanced treatment adoption, however, depends on emergency transport, CT availability, neurosurgical access, stroke-center density, and referral pathways. Large incident volume alone does not translate directly into premium device or drug use.

 

Approved Treatment Landscape

Approved drug use is concentrated in defined hemorrhagic stroke situations. Nimodipine remains the foundational drug in aneurysmal SAH, with FDA labeling for improving neurological outcome after subarachnoid hemorrhage caused by ruptured intracranial aneurysm. Generic availability limits pricing differentiation, but clinical use remains durable because nimodipine is embedded in aSAH care pathways.

PIVLAZ, or clazosentan, has created a distinct Japanese premium-drug segment for aSAH complication prevention. Japan approved and reimbursed the drug for prevention of cerebral vasospasm and related complications after aSAH. Nxera reported JPY 13.511 billion in FY2025 PIVLAZ net sales, 74% patient-based share, and 25,470 cumulative treated patients through December 2025. Japan therefore provides direct evidence that a reimbursed, specialist-focused aSAH therapy can produce measurable revenue when local guideline use, hospital adoption, and reimbursement align.

Anticoagulant reversal remains narrow but high urgency. Praxbind is relevant for dabigatran-associated hemorrhagic stroke because it reverses dabigatran in emergency surgery or life-threatening and uncontrolled bleeding. Four-factor PCC products such as Kcentra remain important in urgent vitamin-K-antagonist reversal and hospital protocols. Factor Xa inhibitor reversal became more constrained after Andexxa’s U.S. exit.

Andexxa reset expectations for branded reversal products in factor Xa inhibitor-associated ICH. FDA safety communications reported higher thrombosis with Andexxa versus usual care, 14.6% versus 6.9%, and thrombosis-related deaths of 2.5% versus 0.9% at 30 days. AstraZeneca’s decision to end U.S. sales removed a differentiated branded option and pushed hospitals toward alternative reversal protocols where safety, speed, formulary control, and specialist oversight carry more weight than hemostatic efficacy alone.

 

Procedure Revenue in aSAH and Selected ICH

Aneurysm repair remains the dominant procedure opportunity in aSAH. The 2023 AHA/ASA guideline recommends treatment of ruptured aneurysms as early as feasible, preferably within 24 hours, using endovascular or surgical treatment selected by a multidisciplinary team. Eligible patients create urgent demand for coils, clips, neurovascular catheters, imaging, operating-room access, interventional neuroradiology, neurosurgery, and ICU follow-up.

External ventricular drainage and hydrocephalus management add procedure and consumable demand in severe hemorrhagic stroke admissions. These products do not address every hemorrhagic stroke case, but they are essential in selected patients with intraventricular extension, hydrocephalus, or raised intracranial pressure. Demand is concentrated in neurocritical care centers that manage high-acuity ICH and SAH patients.

Minimally invasive ICH evacuation is the most active device-led growth area, but adoption depends on patient selection. ENRICH produced positive functional and hospital-utilization results in selected patients, with utility-weighted modified Rankin Scale scores of 0.458 for surgery versus 0.374 for medical management at 180 days and a 98.1% posterior probability of superiority. Stryker also reported ICU length-of-stay reduction of 2.8 days and hospital length-of-stay reduction of 3.1 days for the minimally invasive parafascicular surgery approach. Hospitals have a clearer budget argument when functional improvement is paired with shorter ICU and inpatient use.

Stryker’s 2024 acquisition of NICO gave the ENRICH-supported BrainPath and Myriad technologies a larger commercial channel. ICH evacuation requires more than device availability. Hospitals need trained neurosurgeons, transfer coordination, case selection, imaging workflows, and procedural consistency. A larger neurosurgical sales and training infrastructure improves the chance that positive trial evidence converts into routine use.

Penumbra’s MIND trial created a more cautious device signal. Artemis-assisted evacuation achieved substantial hematoma reduction, including 81.5% ICH volume reduction in the deep cohort and 80.4% in the lobar cohort. The trial did not show a difference in the primary 180-day modified Rankin endpoint after early stoppage. Strong clot removal therefore supports procedural feasibility, but broader clinical claims require better functional-outcome evidence.

 

Acute-Care Protocols Are Reshaping Product Use

ICH care is increasingly organized around standardized acute pathways rather than one standalone drug. INTERACT3 enrolled 7,036 patients and showed that rapid control of blood pressure, glucose, and temperature, along with warfarin reversal, improved six-month functional outcomes. The protocol used measurable treatment targets, including systolic blood pressure below 140 mm Hg, glucose control, temperature at or below 37.5°C, and INR below 1.5 for warfarin-associated ICH.

Hospitals are directing investment toward emergency protocols, antihypertensive access, glucose and temperature monitoring, reversal readiness, imaging turnaround, ICU staffing, and stroke-center transfer systems. Products that reduce mortality, ICU days, discharge to hospice, complications, or poor functional outcomes will face stronger procurement interest than products supported only by radiographic improvement.

Anticoagulant-associated ICH shows the same workflow dependence. In the Get With The Guidelines–Stroke registry, 78.7% of 9,492 anticoagulant-associated ICH patients received reversal therapy. Median door-to-treatment time was 82 minutes, and only 27.7% received treatment within 60 minutes. Faster reversal was associated with lower odds of death or hospice discharge. Reversal-product adoption therefore depends on emergency department protocols, stocking decisions, pharmacy availability, imaging speed, and clinician activation pathways.

 

Pipeline and Trial Direction

ICH drug development remains difficult because early bleeding control has not consistently improved functional outcomes. FASTEST tested recombinant factor VIIa in hyperacute spontaneous ICH. The 2026 Lancet publication reported slower bleeding with rFVIIa but no overall functional-outcome improvement, along with thromboembolic concern. Broad hemostatic use is unlikely without tighter patient selection, earlier administration, or a clearer risk-benefit profile.

Tranexamic acid remains commercially interesting because it is inexpensive, scalable, and relevant to lower-resource systems. TICH-3 and INTRINSIC are important trials because a positive result could create a high-volume acute drug option without the infrastructure burden of advanced devices. Until efficacy is proven in functional outcomes, TXA remains a research pathway rather than a confirmed hemorrhagic stroke treatment market.

IV nimodipine is the most practical near-term formulation opportunity in aSAH. Grace Therapeutics’ GTx-104 is designed as an injectable nimodipine option for aSAH patients, targeting administration problems linked to oral or enteral dosing in critically ill settings. The FDA issued a Complete Response Letter in April 2026 citing CMC and nonclinical deficiencies, while Grace stated that no additional clinical data were requested. Approval remains delayed, but the commercial rationale remains tied to reliable dosing and ICU administration rather than a new mechanism.

Ongoing trials will determine how widely minimally invasive evacuation devices are used in intracerebral haemorrhage. DIST is assessing early endoscopic evacuation, while REACH is studying deep anterior basal-ganglia haemorrhage. ENRICH provides the strongest procedural evidence to date, but wider adoption will depend on consistent functional benefit across different haemorrhage locations, volumes, treatment windows, and hospital settings.

 

Market Structure and Treatment Positioning

Acute and neurocritical care account for the largest treatment volume. Expenditure spans blood pressure management, diagnostic imaging, airway support, intensive care, anticoagulation reversal, seizure treatment, temperature and glucose control, rehabilitation planning, and transfer to specialist centres. Revenue is therefore spread across several clinical categories rather than a single drug segment.

Aneurysm clipping and coiling dominate procedure-led aSAH revenue. Every eligible ruptured aneurysm requires urgent treatment, but device choice depends on anatomy, patient status, center expertise, expected durability, retreatment risk, and reimbursement. Specialist-center concentration gives neurovascular suppliers a clearer commercial path than broad hospital-distribution models.

Generic nimodipine remains clinically essential but price-sensitive. PIVLAZ is premium and geographically concentrated, with Japan providing the strongest evidence of paid drug adoption in aSAH complication prevention. Anticoagulant reversal products serve a smaller emergency population, but safety and formulary restrictions control use. Minimally invasive ICH evacuation is promising where patient selection is strong and hospital economics are visible.

External ventricular drains are used mainly in severe cases complicated by intraventricular hemorrhage, hydrocephalus, or raised intracranial pressure. Demand for related procedures and consumables is concentrated in neurocritical care centres and should not be applied to the entire hemorrhagic stroke population.

 

North America and U.S. Market Behavior

North America leads through comprehensive stroke centers, advanced neurocritical care, FDA-cleared devices, neurointerventional networks, high hospital charges, and structured quality programs. The U.S. ICH admission pool of nearly 79,000 hospitalizations creates meaningful demand, but revenue depends on whether patients reach centers able to deliver rapid reversal, neurosurgery, aneurysm repair, EVD placement, and intensive monitoring.

U.S. device competition is strongest in minimally invasive ICH evacuation and AI-enabled care coordination. Viz.ai and NICO announced a 2024 collaboration to improve ICH care coordination by linking AI detection and volume measurement with surgical pathway activation. Device utilization improves when diagnostic workflow, transfer decisions, and neurosurgical activation are connected.

The U.S. aSAH drug opportunity is mainly formulation-led. Nimodipine is already established, and GTx-104 is attempting to improve ICU administration rather than introduce a new therapeutic pathway. The 2026 Complete Response Letter delays entry, but the absence of a request for additional clinical data keeps the asset commercially relevant if manufacturing and nonclinical issues are resolved.

 

Europe, Japan, China, and Other Regional Signals

Europe’s market is shaped by aging, anticoagulant exposure, hospital utilization, and cost pressure. A German claims study reported annual total costs of EUR 37,328 per ICH patient and 40.4 hospital days per person-year in the first year after ICH among oral FXa inhibitor users. Payers and hospitals have an economic reason to support faster reversal, fewer complications, shorter institutional care, and better discharge outcomes, but expensive products still need functional-outcome evidence.

Japan is the strongest documented premium-drug market for aSAH complication prevention. PIVLAZ reached high patient-based share and more than JPY 13 billion in annual sales. Specialist adoption, reimbursement, and local clinical acceptance converted a defined aSAH complication need into a visible commercial franchise.

China has the largest identified country-level ICH volume, with 1.17 million new ICH cases reported in 2021. Advanced treatment conversion will vary by region because tertiary-center access, emergency transport, CT availability, neurosurgical capacity, and reimbursement depth differ across the country.

India remains data-limited at the niche treatment level. Large stroke burden and active TXA research support future demand, but public evidence is not strong enough to state an exact annual ICH-treated population. Near-term opportunity is more likely to come from affordable acute-care protocols, CT access, blood pressure management, and selective hemostatic research than from broad premium-device penetration.

 

Market Outlook

Hemorrhagic stroke treatment growth will come from better patient selection, faster emergency execution, and stronger functional-outcome evidence. ICH creates the largest acute-care volume, but approved disease-modifying drug options remain limited. aSAH creates a smaller but more concentrated specialist market through aneurysm repair, nimodipine, vasospasm prevention, external ventricular drainage, ICU monitoring, and prolonged inpatient care.

ENRICH-supported minimally invasive evacuation, Japan’s PIVLAZ uptake, protocolized ICH care bundles, rapid anticoagulant reversal, AI-enabled care coordination, and IV nimodipine formulation work provide the strongest commercial signals. Broad hemostatic-drug assumptions remain weak when clot control fails to improve functional recovery.

Device companies will need reproducible patient-selection evidence, neurosurgical training support, and hospital-efficiency data. Drug developers will need safer reversal, reliable aSAH administration, or clear complication reduction. Hospitals will favor interventions that improve survival, independence, ICU utilization, complication rates, or discharge outcomes under high-cost emergency-care conditions.

 

Hemorrhagic Stroke Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.12 Billion
Revenue Forecast in 2032	USD 6.27 Billion
Overall Growth Rate	CAGR of 6.13% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Cause/Condition, By End User, By Geography
By Treatment Type	Drug Therapy, Surgical Intervention, Endovascular Procedures, Monitoring & Supportive Devices
By Cause/Condition	Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Other Rare Hemorrhages
By End User	Tertiary Hospitals, General Hospitals, Ambulatory Surgical Centers
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising intracerebral hemorrhage burden Increasing adoption of neurocritical care protocols Demand for aneurysm repair procedures
Customization Option	Available upon request